Acetyl Dipeptide-1 Cetyl Ester
Skin / Anti-AgingAlso known as: Calmosensine, IRC
Mechanism
A synthetic "feel-good" peptide for skin. It mimics the body's natural endorphins (enkephalins), providing a pleasant sensation when applied topically. Reduces skin discomfort, sensitivity, and has mild anti-inflammatory effects. Used in luxury skincare to create an immediate sense of skin comfort and well-being.
Technical detail
Synthetic lipopeptide mimicking met-enkephalin signaling in cutaneous sensory neurons. Acetyl-dipeptide-1 (acetyl-Tyr-Arg) conjugated to cetyl ester for enhanced skin penetration. Engages delta-opioid receptors (DOR) on peripheral sensory nerve endings in the dermis, modulating nociceptive signaling and reducing substance P release. Anti-inflammatory activity via reduced neurogenic inflammation (decreased CGRP and substance P). Sederma data: significant reduction in skin discomfort scores and improved subjective "well-being" metrics in clinical panels.
Effects
## Integumentary System — Skin Comfort and Sensitivity [Tier 3 — Limited Human Data] Calmosensine (hexapeptide, proprietary sequence by Sederma) is a synthetic peptide designed to mimic the calming effects of endorphins on skin sensory neurons. It is proposed to stimulate mu-opioid receptors on cutaneous sensory nerve endings, reducing the firing threshold and reactivity of C-fibers and A-delta fibers that mediate itch, stinging, and burning sensations. In manufacturer-sponsored studies, application of Calmosensine-containing formulations reduced subjective discomfort (stinging, burning, tightness) in sensitive skin by 55-80% after topical application for 28 days. ## Nervous System — Peripheral Sensory [Tier 3 — In Vitro/Mechanistic Data] In vitro studies show Calmosensine activates mu-opioid receptor (MOR) signaling in cultured sensory neuron-like cells, leading to decreased release of substance P and CGRP — the neuropeptides responsible for neurogenic inflammation and sensory sensitization in skin. This "endorphin-mimetic" mechanism is distinct from traditional anti-inflammatory ingredients (which target immune cells or cyclooxygenase pathways). ## Immune/Inflammatory — Indirect Anti-Inflammatory [Tier 3 — In Vitro Data] By reducing substance P and CGRP release from sensory neurons, Calmosensine indirectly decreases neurogenic inflammation — the mast cell degranulation, vasodilation, and plasma extravasation triggered by sensory neuropeptides. This is a fundamentally different pathway from corticosteroids or NSAIDs.
Practitioner Guide
## Practical Formulation Guide ### Effective Concentrations - **Manufacturer-recommended:** 2-3% of the commercial Calmosensine solution (which is already a dilute preparation of the active peptide in an aqueous base). - **Typical use level in finished product:** 0.001-0.005% active peptide (the commercial solution is not 100% peptide). ### Formulation Considerations - **pH:** Stable at pH 4.5-6.5. Formulate in the typical cosmetic pH range. - **Compatibility:** Compatible with all major cosmetic peptides. Particularly useful in formulations with potentially irritating actives (retinol, AHAs, vitamin C) to offset sensory irritation. - **Best applications:** - Sensitive skin serums and moisturizers - Post-procedure calming treatments (after peels, microneedling, laser) - Rosacea-prone skin care - Products containing high concentrations of actives (retinol, glycolic acid) where irritation limits compliance ### Application Protocol - Apply as part of a serum, before moisturizer. - Particularly effective when applied immediately after potentially irritating treatments. - Can be combined with Argireline and Matrixyl in the same formulation without compatibility issues. ### Realistic Expectations - **Immediate:** Some users report an immediate soothing sensation (within 10-15 minutes) — likely a real but partly placebo-mediated effect. - **2-4 weeks:** Reduction in reactive skin symptoms (stinging on product application, sensitivity to temperature changes) becomes more consistent. - **Limitations:** Calmosensine does not treat the underlying cause of skin sensitivity. It is a symptomatic treatment that reduces sensory nerve reactivity. It will not resolve rosacea, eczema, or dermatitis — but it can reduce the discomfort associated with these conditions.
Research Summary
## Tier 1 — Strong Clinical Evidence - None. No drug regulatory approval. Cosmeceutical ingredient only. ## Tier 2 — Moderate Evidence - Manufacturer-sponsored clinical studies (Sederma, 2004-2010) showing 55-80% reduction in subjective skin discomfort (stinging, burning) in sensitive skin subjects after 28 days (n=20-40 per study) - Instrumental measurements showing reduced skin reactivity to capsaicin and lactic acid sting tests ## Tier 3 — Preclinical/Theoretical - In vitro mu-opioid receptor activation in sensory neuron cultures - Reduced substance P and CGRP release from cultured dorsal root ganglion neurons - Mechanism is biologically plausible (opioid receptors on cutaneous nerves are well-established) but independent validation of the specific peptide's efficacy is limited - No published studies in peer-reviewed dermatology journals (data primarily from manufacturer and cosmetic ingredient trade publications)